

Page 1 of 2

WallStreetResearch.org

NEW YORK, NY LOS ANGELES, CA PALM BEACH, FL



ChineseInvestors.com Inc.

Ticker: (OTCQB: CIIX)

Corporate Profile

as of January 27, 2019

Sector: Media / Internet Industry: Communication Services/Retail

Website: www.ChineseFN.com

Background and History

ChineseInvestors.com, Inc. ("CIIX" or "the Company"), founded in 1999, is headquartered in San Gabriel, California, with offices in New York City, Richmond (Vancouver) BC, and Shanghai, China. The Company focuses on media services geared toward trading and investing in stocks and currencies and investor relations services. In addition to its core business, in 2017 the Company diversified by establishing two consumer product subsidiaries focusing on hemp oil and hemp health care products.

The Company's primary product offering, within its core financial media communications business, is the creation of real-time stock market commentary, analysis, and educational services in the Chinese language (www.ChineseFN.com). Content offered includes information about U.S. publicly-traded stocks, foreign currencies, and now digital currencies, with free quotes, charts, market news, and links to investment research. CIIX also offers paid premium subscription services that include access to sample investment portfolios (for educational purposes), as well as real-time trading demonstrations.

Hemp Subsidiaries Drive Revenue Growth

In recognition of the unprecedented opportunities in the legal industrial hemp industry, in early 2017 CIIX established a Chinese subsidiary offering nonindustrial hemp products direct to consumers. The Company registered XiBiDi Biotechnology Co., Ltd. ("CBD Biotechnology Co., Ltd"), a wholly-owned foreign enterprise, in the Pudong Free-Trade Area in Shanghai and appointed XiangYang Yun as CEO. The Company offers its hemp products online as well as via retail channels including its own flagship retail store. The Company has launched its "CBD Magic Hemp Series" skin care line. In July 2017, CBD Biotechnology Co. Ltd., officially filed a record of its first line of non-industrial hemp-infused skin care products with the China Food and Drug Administration (CFDA). Although there has been published literature by the CFDA indicating that Cannabis can legally be added to skin care products, many Chinese skin care manufacturers have not yet entered this market.



CIIX's Chinese Subsidiary Plans an IPO Later This Year



New Products Include Vitamin Sprays and CBD Combinations

In April 2017, the Company established ChineseHempOil.com, Inc., a wholly-owned U.S. subsidiary. ChineseHempOil.com, Inc. is responsible for the development and operation of online and retail sales of non-industrial hemp-based health products in the United States via its website ChineseHempOil.com. The US subsidiary operates a retail store deemed the "Chinese Wellness Center," in the predominantly Chinese community of San Gabriel, California, in the Los Angeles area. The subsidiarys first CBD oil product line, "OptHemp", a premium private label oil, is manufactured in Colorado using a CO2 Extraction process and has fast become its best seller. "OptHemp" oil sits alongside the Company's other hemp-based products, such as premium hemp gummies, water soluble soft gels, and ointments. These hemp segment subsidiaries have been a major driver of growth for the Company.

Key Statistics

| Price 1/25/2019 | 0.53 | | |
|--|---------|--|--|
| 52 Week High | 1.25 | | |
| 52 Week Low | 0.37 | | |
| Avg. Vol (30day) | 139,670 | | |
| Market Cap (Interday)M | 20.32 | | |
| Price/Sales (TTM) | 7.32 | | |
| Common Shares Outstanding (M) | 39.04 | | |
| Conv. Preferred Shares Outstanding (M) | 8.05 | | |
| Float(M) | 33.27 | | |
| EPS(6mos) | -0.13 | | |
| Beta (3Y Monthly) | 1.51 | | |
| | | | |

Source: Yahoo Finance / OTC Markets

Recent 2018 Highlights

- January 16, 2019 the Company stated it has launched a private brand of CBD Hemp Wine through its wholly-owned foreign enterprise CBD Biotechnology Co. Ltd. Designed specifically for the global Chinese wellness market, Hemp Wine is a proprietary blend made of ingredients including hemp and ginseng.
- January 14, 2019, the Company announced second quarter revenues of \$648,265, up 39% for the quarter.
- December 27, 2018, the Company announced it has retained Boustead Securities, LLC to serve as underwriter for an IPO of CBD Biotech Co. Ltd. The IPO when completed, later in the fall, will provide market visibility and further access to capital.
- October 16, 2018, the Company announced that its subsidiary, CBD Biotechnology Co. Ltd., has entered into Alibaba Group's Tmall (NYSE: BABA), China's largest e-commerce marketplace for global and domestic brands and retailers. This should significantly expand possible sales from its full line of CBD skin-care products to include Alibaba's 500 million registered customers on Taobao and Tmall.

The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to he accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. The featured company will pay a fee of \$4500 in cash to Alan Stone & Company LLC for preparation and distribution of this updated profile, including other potential fees associated with various consulting and investor relation services. For complete disclaimer information, the readers are hereby referred to the Disclaimer Page at the www.WallStreetResearch.org website.



Page 2 of 2

\mathbf{W} all \mathbf{S} treet \mathbf{R} esearch.org

NEW YORK, NY LOS ANGELES, CA PALM BEACH, FL



ChineseInvestors.com Inc.

Ticker: (OTCQB: CIIX)

Corporate Profile

as of January 27, 2019

Sector: Media / Internet **Industry: Communication**

Services/Retail Website: www.ChineseFN.com

New Developments / New Products

The Company's Chinese subsidiary, CBD Biotechnology Co. Ltd., in October 2018, entered into Alibaba Group's (NYSE: BABA) Tmall, China's largest e-commerce marketplace for global and domestic brands and retailers. This distribution strategy will significantly expand the subsidiarys ability to reach Alibaba's 500 million registered customers on the Taobao and Tmall platforms. CBD Biotechnology Co. Ltd.'s new CBD Magic Hemp skin-care product line, is the first CBD skin-care product line to enter Tmall.

CBD Biotechnology Co. Ltd. recently launched its CBD Hemp Wine private brand, hemp-infused rice wine product line. Management believes there are tremendous long-term potential benefits of hemp and rice wine, and rapid revenue growth is anticipated. The Subsidiary is gearing up to launch for the Chinese New Year which begins in early February. On December 4, 2018, the Company announced an agreement with BCDBG, Inc. to exclusively market in Asian markets the complete Vitamist product line. The licensing agreement includes both domestic and international markets and will be for over 40 proprietary vitamin formulas. The Company is currently utilizing the spray technology delivery system for CBD consumption. Under the agreement, BCDBG has developed exclusive and proprietary products for the Company, including vitamin sprays and vitamins/CBD spray combinations.

Financial Results

During the first half, the Company reported \$1,361,000 in total revenue, up 54.1 percent from \$883,000 in the comparable half last year. The Company reported total annual revenues for the year ended May 31, 2018 of \$2.35 million, up 41 percent from the previous year of \$1.67 million. This increase was primarily attributable to increased product sales of its new retail and online product line "OptHemp" in the US; and a variety of Hemp infused products in China. The Company has increased revenue from its various consulting and investor relations services. The Company reported a net loss of \$7.4 million for the year ended May 31, 2018 vs. \$3.3 million net loss in the previous year. Loss per share improved to (\$.58) from (\$.86).

On December 27, 2018 the Company announced it engaged Bousted Securities, LLC to manage an IPO for its CBD Biotechnology Co. Ltd.'s subsidiary, planned to come to market during the fall of 2019. The Company raised \$6.1 million dollars in the last six months through the issuance of Series D Preferred Stock and the sale of Notes. The Company improved its balance sheet by growing total assets to \$6.6 million as of November 30, 2018, and converted a substantial number of preferred shares (multiple series) into common stock, thereby increasing its common share count to 39.04 million. Management anticipates another solid year of revenue growth.

Corporate Contact Information

ChineseInvestors.com Inc.


Warren Wang, CEO Alan Klitenic, Investor Relations (214) 636-2548 227 W. Valley Blvd. Suite 208 A San Gabriel, CA 91776 Email: warrenwang@chinesefn.com Headquarters: (888) 789-1670

www.ChineseInvestors.com www.ChineseFN.com www.ChineseCBDoil.com www.ChineseHempOil.com









| All Jigures beloww are quoted in 03 Dollars and in Thousands | | | | | | | | | | | |
|--|------------|------------|---------------|----------------------------|------------|------------|----------------|-----------------------|------------|------------|---------------|
| Income Statement | FY 5/31/17 | FY 5/31/18 | 6 Mo 11/30/18 | Balance Sheet | FY 5/31/17 | FY 5/31/18 | as of 11/30/18 | Cash Flow Statement | FY 5/31/17 | FY 5/31/18 | 6 Mo 11/30/18 |
| Revenue | \$ 1,668 | 2,353 | 1,361 | Cash | \$ 1,771 | 1,390 | 1,934 | Operating Cash Flow | (4,589) | (7,349) | (5,532) |
| Operating Loss | \$ (4,915) | (7,215) | (4,949) | Total Assets | \$ 3,172 | 3,676 | 6,645 | Investing Cash Flow | 1,412 | (94) | (87) |
| Net Loss | \$ (3,337) | (7,406) | (3,309) | Total Liabilities | \$ 1,781 | 2,751 | 4,775 | Financing Cash Flow | 4,750 | 7,072 | 6,146 |
| Loss Per Share | \$ (0.86) | (0.58) | (0.13) | Total Shareholder's Equity | \$ 1,391 | 926 | 1,871 | Cash at end of period | 1,771 | 1,390 | 1,934 |

The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to he accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. The featured company will pay a fee of \$4500 in cash to Alan Stone & Company LLC for preparation and distribution of this updated profile, including other potential fees associated with various consulting and investor relation services. For complete disclaimer information, the readers are hereby referred to the Disclaimer Page at the www.WallStreetResearch.org website.